42.2% of non-radiographic axial spondyloarthritis patients showed a significant and clinically meaningful reduction in disease activity. More: Cosentyx hits endpoints in axSpA trial Source: News
read moreGilead will now initiate two new clinical trials, for both treatment-naïve and multidrug resistant HIV-1. More: Investigational HIV therapy shows early-stage promise Source: News
read moreThe committee initially published a draft final appraisal for the drug in October, and just last week the SMC approved the treatment for use on NHS Scotland. More: NICE recommends Elmiron for bladder pain syndrome Source: News
read morePatients had 50% fewer flares on the drug compared to placebo. More: Nucala becomes first med to significantly reduce HES flares Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals